rational
rhinovirus
rv
major
trigger
asthma
exacerb
shown
previous
lower
respiratori
tract
symptom
airflow
obstruct
neutrophil
airway
inflamm
increas
experiment
rvinduc
asthma
exacerb
object
hypothes
neutrophilrel
cxc
chemokin
antimicrobi
peptid
increas
relat
clinic
virolog
patholog
outcom
rvinduc
exacerb
asthma
method
protein
level
antimicrobi
peptid
slpi
hnp
elafin
neutrophil
chemokin
determin
bronchoalveolar
lavag
bal
fluid
asthmat
normal
control
taken
day
four
week
postexperiment
infect
result
bal
hnp
elafin
higher
lower
asthmat
compar
control
day
p
p
p
respect
bal
hnp
increas
infect
p
p
respect
trend
increas
bal
neutrophil
day
compar
baselin
p
bal
hnp
posit
correl
bal
neutrophil
number
day
correl
clinic
paramet
level
conclus
propos
rv
infect
asthma
lead
increas
releas
attract
neutrophil
airway
releas
hnp
enhanc
airway
neutrophilia
strategi
inhibit
may
use
treatment
virusinduc
asthma
exacerb
patient
atop
asthma
suscept
lower
respiratori
tract
lrt
infect
sever
longerlast
rhinoviru
rv
induc
lrt
symptom
healthi
individu
viru
infect
respiratori
tract
frequent
associ
asthma
exacerb
rv
predomin
virus
rv
directli
infect
lower
airway
result
increas
lower
respiratori
symptom
reduct
lung
function
bronchial
inflamm
augment
airway
hyperrespons
asthmat
compar
normal
subject
neutrophil
major
effector
cell
defenc
invad
pathogen
number
shown
increas
rv
infect
experiment
model
natur
occur
asthma
exacerb
antimicrobi
peptid
defensin
cathelicidin
famili
compris
signific
part
neutrophil
armamentarium
pathogen
adefensin
hnp
store
primari
azurophil
neutrophil
granul
constitut
total
protein
organel
hypothes
human
rhinoviru
infect
increas
level
adefensin
airway
lead
mark
neutrophil
infiltr
degranul
airway
associ
clinic
sever
virusinduc
asthma
howev
report
directli
measur
defensin
airway
subject
virusinduc
asthma
far
human
cathelicidin
also
releas
neutrophil
upon
inflammatori
stimul
potent
bactericid
activ
slpi
anoth
antimicrobi
peptid
produc
neutrophil
also
alveolar
macrophag
epitheli
cell
may
play
role
acut
exacerb
asthma
role
virusinduc
asthma
unknown
neutrophil
attract
airway
activ
mainli
cxc
chemokin
also
antimicrobi
properti
also
shown
elafin
anoth
antimicrobi
peptid
express
alveolar
macrophag
epitheli
cell
also
chemotact
neutrophil
background
hypothes
antimicrobi
peptid
induc
rv
infect
lower
airway
vivo
test
hypothesi
clarifi
whether
possibl
induct
relat
airway
neutrophilia
express
cxc
chemokin
analys
express
neutrophil
antimicrobi
peptid
cxc
chemokin
bal
fluid
subject
rvinduc
experiment
asthma
exacerb
result
studi
previous
report
abstract
form
studi
design
clinic
lower
airway
inflamm
data
patient
investig
recent
publish
detail
briefli
two
differ
group
studi
first
group
consist
outpati
mild
atop
asthma
second
group
healthi
nonatop
individu
clinic
atop
statu
defin
questionnair
skin
prick
test
serum
ige
lung
function
test
includ
pef
forc
expiratori
volum
fev
forc
vital
capac
fvc
histamin
challeng
perform
accord
guidelin
asthmat
group
concentr
histamin
caus
reduct
fev
pc
mgml
normal
group
mgml
normal
subject
take
medic
asthmat
inhal
shortact
none
asthmat
patient
given
inhal
oralsystem
steroid
time
point
studi
subject
free
common
cold
symptom
week
commenc
studi
nonsmok
bronchoalveolar
lavag
bal
sampl
carri
baselin
week
prior
viru
inocul
day
inocul
acut
infect
week
inocul
convalesc
diari
kept
record
symptom
home
lung
function
throughout
studi
subject
gave
written
inform
consent
studi
approv
st
mari
research
ethic
committe
st
mari
hospit
london
uk
subject
seroneg
neutral
antibodi
titr
screen
repeat
serolog
perform
day
prior
inocul
subject
neg
pcr
panel
respiratori
virus
adenovirus
coronavirus
human
metapneumoviru
influenza
picornavirus
parainfluenza
virus
respiratori
syncyti
viru
mycoplasma
chlamydophila
pneumonia
nasal
lavag
baselin
experiment
infect
induc
use
tcid
day
devillbiss
atom
describ
follow
inocul
subject
return
home
clinic
effect
infect
record
use
daili
diari
card
enabl
calcul
peak
cold
score
total
cold
score
total
week
period
postinocul
peak
total
chest
score
correct
baselin
symptom
effect
bronchoscopi
lung
function
test
home
spirometri
microdl
micromed
carefus
basingstok
uk
histamin
challeng
perform
describ
bronchoalveolar
lavag
collect
singl
plastic
chamber
transfer
immedi
polypropylen
tube
ice
transport
laboratori
aliquot
bal
fluid
store
unprocess
analysi
viru
load
pcr
remain
bal
fluid
centrifug
bal
fluid
store
aliquot
bal
cell
pellet
use
cytospin
prepar
differenti
cell
count
describ
rhinoviru
infect
confirm
subject
use
pcr
cultur
serolog
describ
viru
load
determin
nasal
lavag
unprocess
bal
aliquot
quantit
pcr
describ
bal
fluid
slpi
level
assess
enzymelink
immunosorb
assay
elisa
use
commerci
avail
kit
r
system
abingdon
uk
sensit
pgml
sampl
dilut
hnp
level
measur
elisa
use
commerci
avail
kit
hycult
biotechnolog
uden
netherland
sensit
pgml
sampl
dilut
elafin
human
assess
elisa
kit
cambridg
bioscienc
uk
sensit
pgml
ngml
respect
level
bal
fluid
assess
luminex
analysi
biosourc
luminex
tm
system
sensit
pgml
respect
analys
elisa
use
commerci
avail
kit
r
system
sensit
pgml
well
antigenix
america
inc
huntington
station
ny
usa
sensit
pgml
data
check
normal
distribut
kolmogorovsmirnov
test
normal
distribut
data
present
mean
standard
deviat
wherea
nonnorm
distribut
data
present
median
interquartil
rang
differ
normal
asthmat
group
analys
use
unpair
ttest
normal
distribut
data
mannwhitney
test
nonnorm
distribut
data
discret
variabl
frequenc
report
compar
chisquar
test
fisher
exact
test
appropri
yate
correct
procedur
appli
comparison
differ
infect
baselin
convalesc
analys
use
oneway
repeatedmeasur
anova
normal
distribut
data
spheric
assess
mauchli
test
assumpt
spheric
violat
degre
freedom
correct
use
greenhousegeiss
correct
e
huynhfeldt
correct
e
respect
case
signific
differ
post
hoc
test
bonferroni
correct
perform
case
nonnorm
distribut
data
friedman
test
use
signific
post
hoc
test
wilcoxon
perform
correl
normal
distribut
variabl
examin
use
pearson
correl
coeffici
nonnorm
distribut
variabl
use
spearman
correl
coeffici
respect
twotail
signific
report
signific
level
set
data
analys
process
use
graphpad
prism
graphpad
softwar
inc
la
jolla
ca
usa
spss
intern
busi
machin
corp
armonk
ny
usa
studi
design
analysi
clinic
characterist
clinic
respons
experiment
viral
infect
togeth
extens
data
effect
immun
respons
report
howev
present
complet
new
analysi
data
atop
asthmat
nonatop
normal
control
entir
complet
studi
baselin
characterist
recruit
subject
asthmat
control
report
messag
et
al
recent
one
asthmat
two
normal
volunt
continu
baselin
phase
clinic
characterist
subject
complet
studi
underw
chemokin
antimicrobi
peptid
analys
report
present
studi
summar
tabl
signific
differ
group
concern
age
gender
baselin
fev
featur
allerg
sensit
express
asthmat
group
report
asthmat
patient
show
significantli
higher
total
chest
symptom
score
significantli
higher
maximum
fall
fev
pef
significantli
lower
valu
baselin
day
week
compar
healthi
control
lung
function
impair
induc
rv
infect
correl
increas
neutrophil
bal
asthmat
suggest
role
pmn
rvinduc
exacerb
asthma
signific
differ
viru
load
upper
lower
airway
sampl
two
group
result
summar
tabl
determin
differ
mediat
releas
normal
asthmat
subject
rv
infect
univari
analysi
group
perform
show
bal
paramet
significantli
differ
baselin
interestingli
higher
control
group
compar
asthmat
vs
pgml
p
fig
four
day
infect
bal
hnp
elafin
significantli
higher
asthmat
compar
control
repeatedmeasur
multivari
analysi
show
signific
differ
asthmat
subject
bal
hnp
significantli
increas
day
compar
baselin
fig
tabl
bal
hnp
also
significantli
increas
day
compar
week
asthmat
subject
fig
tabl
trend
increas
bal
neutrophil
day
compar
baselin
asthmat
subject
p
also
measur
bal
signific
differ
observ
neither
within
group
differ
time
point
asthmat
control
time
point
data
shown
relationship
bal
neutrophil
solubl
mediat
viru
load
clinic
paramet
bal
hnp
measur
baselin
neg
correl
bal
viral
load
r
p
asthmat
fig
bal
viral
load
avail
asthmat
subject
unfortun
sampl
got
lost
liquid
nitrogen
thaw
christmasnew
year
avail
analysi
bal
hnp
baselin
correl
bal
baselin
asthmat
r
p
bal
hnp
paramet
posit
correl
rel
bal
neutrophil
number
day
postinfect
subject
fig
week
bal
hnp
also
correl
bal
r
p
subject
bal
level
day
postinfect
correl
peak
nasal
lavag
viru
load
r
p
r
p
respect
asthmat
bal
week
correl
bal
neutrophil
nonepitheli
cell
r
p
subject
correl
clinic
paramet
fev
pef
level
elafin
level
day
postinfect
invers
relat
maxim
fall
pef
r
p
asthmat
fig
investig
effect
rv
infect
express
cxc
chemokin
antimicrobi
peptid
human
experiment
model
rvinduc
asthma
exacerb
show
accord
turner
et
al
neutrophilattract
chemokin
significantli
increas
asthmat
compar
normal
control
bal
neutrophil
tend
increas
asthmat
day
compar
normal
control
number
relat
hnp
level
significantli
higher
level
antimicrobi
peptid
hnp
releas
airway
asthmat
patient
compar
normal
control
infect
respiratori
infect
main
trigger
asthma
exacerb
respiratori
virus
frequent
pathogen
human
rv
frequent
detect
shown
natur
occur
virusinduc
asthma
exacerb
neutrophil
recruit
airway
part
immun
defenc
influx
neutrophil
correl
symptom
paramet
airway
obstruct
fev
accordingli
observ
experiment
model
higher
valu
bal
neutrophil
day
intranas
experiment
infect
howev
chang
moder
probabl
due
small
number
patient
rather
mild
sever
induc
asthma
exacerb
recruit
intens
burdensom
studi
difficult
result
small
number
patient
moreov
also
due
ethic
constraint
experiment
exacerb
mild
charact
result
present
thu
also
consequ
requir
symptom
reduct
fev
significantli
greater
asthmat
compar
control
previous
report
shown
day
experiment
rv
infect
inflammatori
respons
upper
airway
increas
associ
increas
symptom
airway
obstruct
asthmat
report
increas
neutrophil
associ
higher
hnp
level
suggest
neutrophil
could
major
sourc
hnp
knowledg
cell
type
hnp
express
shown
cdcd
cell
blood
henc
expect
relev
cellular
sourc
hnp
neutrophil
bal
favour
also
fact
chemokin
significantli
increas
day
asthmat
shown
hnp
induc
may
explain
certain
degre
significantli
higher
level
observ
day
significantli
higher
level
trend
higher
bal
day
relat
high
viru
load
measur
nasal
lavag
may
result
increas
induct
asthmat
rv
shown
vitro
rv
infect
human
respiratori
epitheli
cell
line
significantli
increas
moreov
demonstr
intramuscular
inject
synthet
induc
transcript
express
gene
encod
proinflammatori
cytokin
tnfalpha
chemokin
furthermor
show
chemotact
capac
toward
leucocyt
find
suggest
rv
infect
induc
chemotact
activ
toward
neutrophil
therebi
increas
neutrophil
number
airway
releas
hnp
properti
enhanc
neutrophilia
howev
acknowledg
possibl
increas
defensin
express
could
also
epiphenomenon
neutrophil
activ
mechan
releas
reactiv
oxygen
speci
proinflammatori
mediat
may
least
also
contribut
drive
asthma
exacerb
cxc
chemokin
investig
chemoattract
neutrophil
major
effector
cell
asthma
exacerb
viral
airway
infect
interestingli
signal
common
receptor
requir
rv
induct
neutrophil
airway
inflamm
develop
airway
hyperrespons
recent
demonstr
mous
model
henc
could
interest
target
therapi
rvinduc
asthma
exacerb
specif
receptor
antagonist
alreadi
clinic
develop
might
rv
infect
lead
increas
express
human
neutrophil
peptid
antimicrobi
peptid
hnp
import
effector
molecul
neutrophil
suggest
adefensin
hnp
directli
inactiv
nonenvelop
virus
rv
howev
recent
research
show
complet
true
shown
human
adefensin
block
adenoviru
uncoat
moreov
known
hnp
potent
antagonist
infect
cutan
mucos
papillomaviru
type
block
virion
escap
endocyt
vesicl
thu
hnp
direct
antivir
properti
nonenvelop
virus
might
also
direct
antivir
properti
rv
infect
addit
hnp
might
indirect
antivir
effect
recent
shown
inhibit
replic
even
ad
h
postinfect
moreov
demonstr
affect
abil
adenovirus
infect
epitheli
cell
adefensin
chemoattract
properti
toward
cell
increas
level
adefensin
viral
infect
could
therefor
recruit
cell
airway
may
enhanc
antivir
immun
shown
varieti
murin
model
hnp
enhanc
antigenspecif
humor
cellular
immun
howev
one
bear
mind
laid
increas
defensin
express
could
also
epiphenomenon
airway
neutrophila
consid
contribut
asthma
exacerb
elafin
level
significantli
higher
asthmat
day
compar
normal
control
time
higher
hnp
howev
elafin
level
significantli
increas
day
compar
baselin
convalesc
elafin
level
day
postinfect
invers
relat
maxim
fig
relationship
bronchoalveolar
lavag
bal
hnp
level
bal
viral
load
day
postinfect
investig
two
subject
group
asthmat
group
signific
invers
correl
hnp
bal
viral
load
day
postinfect
present
normal
group
b
relationship
bal
hnp
level
bal
neutrophil
day
postinfect
investig
two
subject
group
asthmat
group
signific
correl
hnp
bal
neutrophil
day
postinfect
relationship
observ
normal
group
c
relationship
bal
elafin
level
day
postinfect
peak
flow
maxim
fall
investig
two
subject
group
asthmat
group
signific
invers
correl
bal
elafin
peak
flow
maxim
fall
day
postinfect
present
normal
group
fall
pef
correl
absenc
signific
increas
respons
rv
infect
probabl
due
low
subject
number
must
interpret
caution
might
suggest
insuffici
express
molecul
might
lead
pronounc
function
consequ
rv
infect
asthmat
howev
support
experiment
andor
clinic
studi
bal
level
significantli
lower
asthmat
day
compar
control
shown
ferret
model
use
microarray
analysi
infect
induc
express
multipl
chemokin
includ
recent
studi
found
increas
express
associ
neutrophil
activ
sever
stabl
copd
seem
play
role
local
innat
immun
respons
dysregul
express
molecul
might
result
neutrophil
dysfunct
clearli
hypothesi
investig
studi
strength
weak
major
strength
studi
studi
design
experiment
rv
infect
human
provid
excel
model
virusinduc
asthma
control
condit
includ
applic
standard
dose
singl
viru
serotyp
standard
clinic
data
collect
invas
sampl
carri
control
condit
repeatedli
accur
defin
time
point
howev
elabor
studi
design
extrem
labourintens
account
limit
number
subject
includ
studi
thu
subject
number
small
safeti
reason
mild
asthmat
could
includ
studi
limit
abil
studi
sever
form
asthma
anoth
import
aspect
bal
sampl
time
point
limit
due
invas
charact
investig
seem
possibl
time
point
chosen
baselin
day
week
experiment
infect
correspond
peak
chang
cxc
chemokin
amp
express
moreov
analysi
solubl
marker
respiratori
secret
complex
dilut
modif
degrad
nevertheless
found
signific
differ
asthmat
normal
control
result
meticul
patient
character
inclus
regard
vitro
find
preliminari
vivo
data
result
deliv
direct
evid
rv
infect
increas
level
adefensin
airway
assum
rv
infect
lead
mark
neutrophil
infiltr
degranul
airway
find
possibl
import
neutrophil
degranul
associ
clinic
sever
virusinduc
asthma
first
studi
show
increas
express
neutrophil
antimicrobi
peptid
welldefin
human
model
experiment
rhinovir
infect
asthmat
propos
rv
infect
asthma
lead
increas
releas
therebi
attract
neutrophil
airway
releas
hnp
enhanc
airway
neutrophilia
studi
warrant
better
understand
role
import
cell
molecul
asthma
exacerb
order
identifi
possibl
new
target
therapi
author
contribut
gr
involv
hypothesi
delin
analysi
interpret
data
wrote
manuscript
sdm
involv
concept
hypothes
delin
design
studi
analysi
interpret
data
substanti
involv
revis
manuscript
prior
submiss
jh
tk
hp
vl
involv
acquisit
data
analysi
interpret
data
mrk
omk
la
pm
mre
involv
concept
hypothes
delin
design
studi
acquisit
data
analysi
substanti
revis
manuscript
prior
submiss
slj
involv
concept
hypothes
delin
design
studi
analysi
interpret
data
write
revis
articl
prior
submiss
